Stem cell therapy research can be carried out in terminally ill patients who are dying of neurodegenerative disorders as benefits are more than the risk involved in these patients, views Professor Ian Wilmut, the creator of first cloned dolly sheep. Professor Wilmut is appointed as the first director to the centre of Regenerative Medicine, Edinburgh University.
Professor Wilmut feels that stem cell research though in infant stage has great potential to treat neurodegenerative disorders and other chronic genetic diseases. Stem cell researchers are eagerly waiting for a positive announcement on stem cell policy which is to be announced on New Year eve by UK Health Secretary Patricia Hewitt. Though stem cell research may cause genetic alterations and adverse effects, the benefits of stem cell research is higher than its side effects.